acetylcysteine has been researched along with Cryptogenic Fibrosing Alveolitis in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (4.35) | 29.6817 |
| 2010's | 58 (84.06) | 24.3611 |
| 2020's | 8 (11.59) | 2.80 |
| Authors | Studies |
|---|---|
| Banfield, L; Coyne, J; Cui, S; Guy, B; Helmeczi, W; Husnudinov, R; Jones, A; Khalid, MF; Kolb, MR; Mah, J; Pitre, T; Scallan, C; Su, J; Zeraatkar, D; Zhang, M | 1 |
| Cao, F; Jiao, Y; Li, G; Liu, H; Pang, Q; Wei, W | 1 |
| Cooper, CB; Flaherty, KR; Kim, JS; Lasky, JA; Martinez, FJ; Murray, S; Noth, I; Oldham, JM; Podolanczuk, AJ; Raghu, G; Spino, C | 1 |
| Singh, S; Wairkar, S | 1 |
| Cao, Y; Zhang, XL; Zheng, B | 1 |
| Bonella, F; Kreuter, M; Li, X; Oltmanns, U; Peng, S; Shi, H; Wei, L; Yin, D | 1 |
| Bando, M; Hattori, N; Homma, S; Inase, N; Johkoh, T; Kataoka, K; Kato, M; Kishaba, T; Kishi, K; Kondoh, Y; Kuwano, K; Mukae, H; Nishioka, Y; Okamoto, M; Saito, T; Sakai, F; Sakamoto, S; Sasaki, S; Suda, T; Taguchi, Y; Takizawa, H; Tanino, Y; Yatera, K | 1 |
| Noth, I; Podolanczuk, AJ; Raghu, G | 1 |
| Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H | 1 |
| Adegunsoye, A; Chen, LW; Chung, JH; Hsu, S; Husain, A; Lee, C; Montner, S; Noth, I; Oldham, JM; Strek, ME; Vij, R; Witt, LJ | 1 |
| Azuma, A; Bando, M; Date, H; Ebina, M; Fukuoka, J; Gemma, A; Goto, Y; Hasegawa, Y; Hattori, N; Homma, S; Inase, N; Inoue, Y; Ishii, Y; Izumi, S; Johkoh, T; Kido, T; Kishaba, T; Kishi, K; Miyamoto, A; Mukae, H; Nakayama, T; Nishioka, Y; Ogura, T; Sakamoto, S; Sasaki, S; Suda, T; Sugino, K; Taguchi, Y; Takahashi, H; Takahashi, K; Taniguchi, H; Watanabe, K; Yokoyama, A; Yoshino, I | 1 |
| Blokland, KEC; Burgess, JK; Grainge, C; Hogaboam, CM; Jaffar, J; Khalil, N; Knight, DA; Mutsaers, SE; Pechkovsky, DV; Prêle, CM; Read, J; Reid, AT; Schuliga, M; Waters, DW; Westall, G | 1 |
| Guo, J; Li, B; Li, W; Pan, Y; Wang, F; Wang, Z; Wu, Y | 1 |
| Chen, MJ; Ding, YX; Tong, ZQ; Yang, GL | 1 |
| Beuschel, RT; Bui, SN; Cannon, B; Chhina, MK; Ellis, E; Grant, GM; Lemma, M; Liberti, EM; Nathan, SD; Rodriguez, LR | 1 |
| Liu, JP; Lv, XD; Pang, LJ | 1 |
| Gasbarrini, A; Gibiino, G; Richeldi, L; Varone, F | 1 |
| Hashemi Sadraei, N; Masjedi, MR; Riahi, T | 1 |
| Alfaro, TM; Cordeiro, CR; Freitas, S | 1 |
| Ancochea, J; Bollo, E; Fernández-Fabrellas, E; Franquet, T; Molina-Molina, M; Montero, MA; Serrano-Mollar, A; Xaubet, A | 1 |
| Bodlet, A; Dahlqvist, C; Jamart, J; Maury, G | 1 |
| Ancochea, J; Valenzuela, C | 1 |
| Kondoh, Y; Taniguchi, H | 1 |
| Homma, S; Ishida, F; Isobe, K; Itoh, T; Muramatsu, Y; Sakamoto, S; Satoh, K; Sugino, K | 1 |
| Aguilaniu, B; Bouquillon, B; Cadranel, J; Carré, P; Cordier, JF; Cottin, V; Crestani, B; Dalphin, JC; Danel, C; Delaval, P; Faivre, JB; Ferreti, G; Israel-Biet, D; Just, N; Kessler, R; Kouzan, S; Lebargy, F; Marchand Adam, S; Philippe, B; Prévot, G; Reynaud-Gaubert, M; Stach, B; Thivolet-Béjui, F; Valeyre, D; Wallaert, B | 1 |
| Zhang, DP | 1 |
| Anstrom, KJ; de Andrade, JA; King, TE; Martinez, FJ; Raghu, G | 1 |
| Collard, HR; Ryerson, CJ | 1 |
| Ehlers-Tenenbaum, S; Herth, FJ; Heussel, CP; Kahn, N; Kreuter, M; Oltmanns, U; Palmowski, K; Puderbach, M; Schnabel, PA; Träger, A; Warth, A; Wenz, H; Wiebel, M | 1 |
| Kang, S | 1 |
| Covvey, JR; Mancl, EE | 1 |
| Cottin, V | 1 |
| Homma, S; Sakamoto, S; Sugino, K | 1 |
| Homma, S; Ishida, F; Isobe, K; Kikuchi, N; Muramatsu, Y; Sakamoto, S; Sano, G; Satoh, K; Sugino, K; Takai, Y | 1 |
| Nambiar, AM; Velez, MI | 1 |
| Einecke, D | 1 |
| Andreas, S; Bahmer, T; Behr, J; Claussen, M; Gläser, S; Grohé, C; Held, M; Herth, FJ; Hoeper, MM; Höffken, G; Huber, RM; Kirschner, J; Klotsche, J; Koch, A; Kohlhäufl, M; Koschel, D; Kreuter, M; Meyer, FJ; Neurohr, C; Pittrow, D; Randerath, W; Schwaiblmair, M; Skowasch, D; Welte, T; Wilkens, H; Wirtz, H | 1 |
| Clegg, AJ; Colquitt, JL; Copley, VR; Loveman, E; O'Reilly, KM; Scott, DA | 1 |
| Anstrom, KJ; Huang, Y; Lee, C; Ma, SF; Martinez, FJ; Noth, I; Oldham, JM; Raghu, G; Schwartz, DA; Strek, ME; Valenzi, E; Vij, R; Witt, L | 1 |
| Lozano-Wilhelmi, M | 1 |
| Blackwell, TS; Kropski, JA; Lawson, WE | 1 |
| Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G | 1 |
| Beyene, J; Brozek, J; Garcia, CC; Neupane, B; Raghu, G; Richeldi, L; Rochwerg, B; Schünemann, H; Zhang, Y | 1 |
| Amano, M; Honda, K; Kawabe, R; Matsubayashi, M; Matsushima, H; Nishizawa, T; Oba, T; Okuda, R | 1 |
| Homma, S; Ishida, F; Morita, T; Muramatsu, Y; Sugino, K; Tatebe, J | 1 |
| Collard, HR; Wijsenbeek, MS | 1 |
| Albera, C; Beck, J; Behr, J; Bendstrup, E; Crestani, B; Günther, A; Koschel, D; Kreuter, M; Lin, CY; Olschewski, H; Sköld, CM; Wallaert, B; Wells, A; Wuyts, W | 1 |
| Liu, J; Sun, T; Zhao, W | 1 |
| Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Rogliani, P | 1 |
| Biju, G; Jyothi, E; Kumar, NK; Narayan, KV; Suraj, KP | 1 |
| Che, C; Chi, F; Dong, F; Liu, L; Song, Q; Wang, Y; Zhang, C; Zhang, L | 1 |
| Guo, F; Song, X; Yu, W | 1 |
| Martinez, F; Noth, I; Raghu, G | 1 |
| Albera, C; Behr, J; Crestani, B; Kirchgaessler, K; Wells, A | 1 |
| Chang, S; Diamantopoulos, A; Esser, D; LeReun, C; Maher, TM; Rinciog, C; Watkins, M | 1 |
| Wolters, PJ | 1 |
| Behr, J; Boissard, G; Buhl, R; Costabel, U; De Vuyst, P; Dekhuijzen, RP; Demedts, M; Flower, CD; Jansen, HM; Lankhorst, I; Laurent, F; MacNee, W; Nicholson, AG; Petruzzelli, S; Rodriguez-Becerra, E; Sardina, M; Thomeer, M; van den Bosch, JM; Verbeken, EK; Verschakelen, J; Wallaert, B | 1 |
| Eckman, MH; Hagaman, JT; Kinder, BW | 1 |
| Costabel, U; Cu, A; Guzman, J; Nakamura, S; Sarria, R; Ye, Q | 1 |
| Bando, M; Hosono, T; Mato, N; Nakaya, T; Ohno, S; Sugiyama, Y; Yamasawa, H | 1 |
| Agnese, S; Avvedimento, EV; Bocchino, M; Fagone, E; Gabrielli, A; Grieco, D; Sanduzzi, A; Svegliati, S; Vancheri, C | 1 |
| Behr, J; Costabel, U; Worth, H | 1 |
| McGrath, EE; Millar, AB | 1 |
| Azuma, A; Homma, S; Kudoh, S; Mochiduki, Y; Nakata, K; Ogura, T; Sugiyama, Y; Takeuchi, M; Taniguchi, H; Yoshimura, K | 1 |
| Elton, TS; Gupta, NN; Gurney, TO; Haley, BE; Kotha, SR; Magalang, UJ; Malireddy, S; Marsh, CB; Parinandi, NL; Patel, RB; Sauers, LA | 1 |
| Behr, J | 1 |
| Behr, J; Costabel, U; Cottin, V; Poletti, V; Wells, AU | 1 |
| Chen, L; Li, J; Li, S; Li, W; Su, X; Yan, G; Yang, X | 1 |
| Adamali, HI; Maher, TM | 1 |
18 review(s) available for acetylcysteine and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
Topics: Acetylcysteine; Adult; Azathioprine; Humans; Idiopathic Pulmonary Fibrosis; Network Meta-Analysis; Sildenafil Citrate | 2022 |
Clinical efficacy of Chinese herbs for supplementing qi and activating blood circulation combined with N-acetylcysteine in the treatment of idiopathic pulmonary fibrosis: A systematic review and network meta-analysis.
Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Network Meta-Analysis; Oxygen; Qi; Treatment Outcome | 2022 |
Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome | 2023 |
Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis.
Topics: Acetylcysteine; Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity | 2020 |
Japanese guideline for the treatment of idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Glycine; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Japan; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic; Prognosis; Pyridones; Quality of Health Care; Sulfonamides; Survival Rate | 2018 |
Chinese herbal medicines compared with N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: Protocol for a systematic review.
Topics: Acetylcysteine; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Idiopathic Pulmonary Fibrosis; Quality of Life; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Total Lung Capacity; Treatment Outcome | 2018 |
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy.
Topics: Acetylcysteine; Anti-Bacterial Agents; Antioxidants; Colistin; Disease Progression; Drug Synergism; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Lung; Microbiota | 2019 |
[How to face the current status of therapies for idiopathic pulmonary fibrosis].
Topics: Acetylcysteine; Clinical Trials as Topic; Drug Therapy, Combination; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Prognosis; Pyridones | 2013 |
Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents; Azathioprine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Prednisone; Pyridones; Randomized Controlled Trials as Topic | 2014 |
Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment.
Topics: Acetylcysteine; Empirical Research; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Japan; Oximetry; Patient Selection; Pyridones; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Vital Capacity | 2015 |
Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2015 |
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin | 2016 |
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Topics: Acetylcysteine; Adult; Anticoagulants; Bayes Theorem; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Male; Middle Aged; Pyridones; Quality of Life; Treatment Outcome; Young Adult | 2016 |
Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Topics: Acetylcysteine; Expectorants; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Diffusing Capacity; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity | 2016 |
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Topics: Acetylcysteine; Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Markov Chains; Models, Economic; Pyridones; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2017 |
[Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment].
Topics: Acetylcysteine; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antioxidants; Biopsy; Expectorants; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Pyridones; Tomography, X-Ray Computed | 2012 |
Current and novel drug therapies for idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Amino Acid Oxidoreductases; Animals; Antiviral Agents; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-13; Lung Transplantation; MicroRNAs; Protein Kinase Inhibitors; Pyridones; Transforming Growth Factor beta | 2012 |
9 trial(s) available for acetylcysteine and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
Topics: Acetylcysteine; Clinical Trials, Phase III as Topic; Double-Blind Method; Genotype; Humans; Idiopathic Pulmonary Fibrosis; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity | 2022 |
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Japan; Pyridones; Treatment Outcome; Vital Capacity | 2021 |
Treatment switching in idiopathic pulmonary fibrosis: from triple therapy to enrollment into a clinical investigational drug trial.
Topics: Acetylcysteine; Azathioprine; Double-Blind Method; Drugs, Investigational; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Treatment Outcome | 2013 |
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Treatment Failure; Vital Capacity | 2014 |
Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: A prospective, single-arm study.
Topics: Acetylcysteine; Administration, Inhalation; Aged; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Respiratory Function Tests; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Therapy, Combination; Europe; Expectorants; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome | 2016 |
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Exercise Test; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Patient Dropouts; Prednisone; Pulmonary Diffusing Capacity; Respiratory System Agents; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity | 2009 |
[Comments of the DGP on the press release dated 21.10. 2011 of the National Heart, Lung and Blood Institute about the PANTHER Study on IPF patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Azathioprine; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Middle Aged; Placebos; Prednisolone; Randomized Controlled Trials as Topic; Respiratory System Agents; Treatment Outcome | 2011 |
Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Aged; Asian People; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Vital Capacity | 2012 |
42 other study(ies) available for acetylcysteine and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Long-circulating thiolated chitosan nanoparticles of nintedanib with N-acetyl cysteine for treating idiopathic pulmonary fibrosis: In vitro assessment of cytotoxicity, antioxidant, and antifibrotic potential.
Topics: Acetylcysteine; Antioxidants; Cell Line; Cell Survival; Chitosan; Humans; Idiopathic Pulmonary Fibrosis; Nanoparticles; Particle Size; Sulfhydryl Compounds | 2023 |
Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with
Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Vital Capacity | 2021 |
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2018 |
N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia.
Topics: Acetylcysteine; Aged; Antibodies, Antinuclear; Cohort Studies; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2018 |
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts.
Topics: Acetylcysteine; Biomarkers; Cellular Senescence; Cyclic N-Oxides; Down-Regulation; Etoposide; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mitochondria; Myofibroblasts; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rotenone; Sirolimus | 2018 |
Efficacy of TCM therapy of tonifying lung-kidney's Qi-deficiency in a case of idiopathic pulmonary fibrosis: A case report.
Topics: Acetylcysteine; Carbon Monoxide; Disease Progression; Expectorants; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Kidney; Lung; Male; Medicine, Chinese Traditional; Middle Aged; Pulmonary Diffusing Capacity; Respiratory Function Tests; Treatment Outcome; Vital Capacity; Yin Deficiency | 2019 |
Curcumin induced oxidative stress attenuation by N-acetylcysteine co-treatment: a fibroblast and epithelial cell in-vitro study in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Antioxidants; Cell Survival; Cells, Cultured; Curcumin; Epithelial Cells; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Oxidative Stress; Polymerase Chain Reaction; Reactive Oxygen Species | 2019 |
Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Medicine, Chinese Traditional; Meta-Analysis as Topic; Network Meta-Analysis; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Respiratory Function Tests; Severity of Illness Index; Survival Analysis; Systematic Reviews as Topic | 2019 |
Idiopathic pulmonary fibrosis in a referral center in Iran: are patients developing the disease at a younger age?
Topics: Acetylcysteine; Adolescent; Adrenal Cortex Hormones; Adult; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Child; Drug Therapy, Combination; Expectorants; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Iran; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Young Adult | 2013 |
Clinical case: Differential diagnosis of idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Alveolitis, Extrinsic Allergic; Azathioprine; Diagnosis, Differential; Disease Management; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Prednisolone; Pulmonary Emphysema; Radiography; Smoking | 2013 |
Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases.
Topics: Acetylcysteine; Biopsy; Bronchoalveolar Lavage Fluid; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Contraindications; Diagnostic Imaging; Disease Progression; Evidence-Based Medicine; Gastroesophageal Reflux; Genetic Therapy; Glucocorticoids; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Incidence; Indoles; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Palliative Care; Prevalence; Prognosis; Pulmonary Emphysema; Pyridones; Risk Factors; Spain | 2013 |
Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Oxygen Inhalation Therapy; Pulmonary Diffusing Capacity; Pulmonary Emphysema; Respiratory Function Tests; Retrospective Studies; Syndrome; Tomography, X-Ray Computed; Total Lung Capacity; Vital Capacity | 2013 |
Combination therapies targeting multiple pathways in idiopathic pulmonary fibrosis (IPF).
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Vital Capacity | 2013 |
Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity | 2013 |
[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française].
Topics: Acetylcysteine; Adrenal Cortex Hormones; Antibodies; Anticoagulants; Colchicine; Diagnostic Techniques, Respiratory System; France; Genetic Testing; Humans; Idiopathic Pulmonary Fibrosis; Interdisciplinary Communication; Patient Care Team; Vaccination | 2013 |
Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2014 |
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Expectorants; Fatigue; Female; Gastrointestinal Diseases; Germany; Humans; Idiopathic Pulmonary Fibrosis; Male; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Vital Capacity; Weight Loss | 2014 |
2014 American Thoracic Society International Conference.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Asthma; Congresses as Topic; Eosinophilia; Expectorants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridones; Respiratory Distress Syndrome | 2014 |
[Idiopathic pulmonary fibrosis: A new era, new challenges].
Topics: Acetylcysteine; Clinical Trials as Topic; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2014 |
Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
Topics: Acetylcysteine; Administration, Inhalation; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity | 2015 |
Combination pirfenidone and inhaled N-acetylcysteine therapy for IPF: does it take these two to tango?
Topics: Acetylcysteine; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones | 2015 |
[Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time].
Topics: Acetylcysteine; Disease Progression; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Vital Capacity | 2015 |
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.
Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Exercise Test; Female; Germany; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyridones; Registries; Steroids; Tomography, X-Ray Computed; Vital Capacity | 2015 |
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.
Topics: Acetylcysteine; Aged; Cohort Studies; Female; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Intracellular Signaling Peptides and Proteins; Male; Mucin-5B; Polymorphism, Single Nucleotide; Risk | 2015 |
Genetics affect IPF treatment response to N-acetylcysteine.
Topics: Acetylcysteine; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis | 2015 |
Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?
Topics: Acetylcysteine; Female; Humans; Idiopathic Pulmonary Fibrosis; Intracellular Signaling Peptides and Proteins; Male; Mucin-5B | 2015 |
Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Aged; Disease Progression; Female; Glutathione; Glutathione Disulfide; Humans; Idiopathic Pulmonary Fibrosis; Male; Retrospective Studies; ROC Curve; Vital Capacity | 2016 |
Acetylcysteine in IPF: the knockout blow?
Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Pyridones | 2016 |
Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Proton Pump Inhibitors; Pyridones; Treatment Outcome | 2016 |
Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis.
Topics: Acetylcysteine; Aged; Anti-Bacterial Agents; China; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Oxygen Inhalation Therapy; Prognosis; Pulmonary Emphysema; Retrospective Studies; Severity of Illness Index; Survival Analysis; Tomography, X-Ray Computed; Vital Capacity | 2016 |
Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
Topics: Acetylcysteine; Animals; Bleomycin; Blotting, Western; Caveolin 1; Cytoprotection; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Idiopathic Pulmonary Fibrosis; Lung; Male; Platelet-Derived Growth Factor; Prednisone; Protective Agents; Pyridones; Rats, Wistar; Real-Time Polymerase Chain Reaction; Signal Transduction; Time Factors; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2017 |
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open.
Topics: Acetylcysteine; Administration, Inhalation; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Vital Capacity | 2017 |
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply.
Topics: Acetylcysteine; Administration, Inhalation; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Vital Capacity | 2017 |
Could N-acetylcysteine slow progression of idiopathic pulmonary fibrosis by inhibiting EMT?
Topics: Acetylcysteine; Animals; Disease Progression; Drug Therapy, Combination; Epithelium; Humans; Idiopathic Pulmonary Fibrosis; Mesoderm; Pulmonary Alveoli; Rats | 2009 |
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.
Topics: Acetylcysteine; Azathioprine; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; Gene Frequency; Genetic Testing; Genotype; Humans; Idiopathic Pulmonary Fibrosis; Leukopenia; Methyltransferases; Models, Economic; Patient Selection; Pharmacogenetics; Phenotype; Quality-Adjusted Life Years; Respiratory System Agents; Steroids; Treatment Outcome | 2010 |
N-acetylcysteine inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro.
Topics: Acetylcysteine; Aged; Bronchoalveolar Lavage Fluid; Cells, Cultured; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Macrophages, Alveolar; Male; Receptors, Tumor Necrosis Factor; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2009 |
Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Aged; Case-Control Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Respiratory Function Tests; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Actins; Blotting, Western; Cell Differentiation; Cell Survival; Cells, Cultured; Collagen Type I; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Free Radical Scavengers; Humans; Hydrogen Peroxide; Idiopathic Pulmonary Fibrosis; Middle Aged; Muscle, Smooth; Oxidants; Phosphorylation; Protein-Tyrosine Kinases; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1 | 2010 |
Hot off the breath: triple therapy for idiopathic pulmonary fibrosis--hear the PANTHER roar.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Azathioprine; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Middle Aged; Placebos; Prednisolone; Randomized Controlled Trials as Topic; Respiratory System Agents | 2012 |
Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercap
Topics: Acetylcysteine; Actin Cytoskeleton; Animals; Antioxidants; Bleomycin; Cattle; Cell Culture Techniques; Cell Survival; Cells, Cultured; Cysteamine; Endothelial Cells; Endothelium, Vascular; Glutathione; Idiopathic Pulmonary Fibrosis; Lung; Microscopy, Fluorescence; Molecular Structure; Oxidation-Reduction; Phthalic Acids; Reactive Oxygen Species; Structure-Activity Relationship; Sulfhydryl Compounds | 2012 |
Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.
Topics: Acetylcysteine; Azathioprine; Drug Therapy, Combination; Expectorants; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Prednisolone | 2012 |
N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats.
Topics: Acetylcysteine; Actins; Animals; Antibiotics, Antineoplastic; Bleomycin; Collagen; Disease Models, Animal; Down-Regulation; Free Radical Scavengers; Glutathione; Idiopathic Pulmonary Fibrosis; Lung; Male; Protein-Lysine 6-Oxidase; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1 | 2012 |